First biomarker to detect underlying neuropathology in FTD identified
A study published in the journal Nature Medicine and conducted by researchers from IR Sant Pau has identified this biomarker, which plays a key role in opening up new possibilities for the differential diagnosis of neurodegenerative pathologies such as FTD, ALS or PSP.
A study published in the prestigious scientific journal Nature Medicine has identified the first biomarker that allows us to identify the underlying neuropathology in frontotemporal dementia (FTD) and differentiate two proteins that accumulate in the brain in this neurodegenerative disease. Researchers from the Neurobiology of Dementia and … + read more
Innovative method for diagnosing Alzheimer’s disease with over 90% accuracy
The p-tau217 biomarker showed 90 to 95% accuracy in detecting abnormal beta-amyloid and TAU protein deposits, comparable to traditional biomarkers in cerebrospinal fluid. + read more
Catalonia, a world leader in clinical research
88.5% of this type of research carried out in Spain is carried out in this region. Most of it is focused on cancer treatment, mainly due to the pharmaceutical industry. + read more
A simple biomarker for prognosis of colorectal cancer at several stages
Preoperative white blood cell count is an independent predictor of survival in patients undergoing resection, according to a new study. + read more
Intrathecal biomarker reflects the degree of activity of multiple sclerosis.
CD27 levels may help personalize treatment and track its impact on disease progression, according to a new study. + read more
They have found a key biomarker for severe liver disease in infants.
Alpha-1 antitrypsin deficiency is considered a genetic disorder that affects one in 3,500 people and has more than 100 variants, including the ZZ genotypes, which increase the risk of lung and liver disease in both children and adults. + read more
Quality of life and progression-free survival go hand in hand in lung cancer
The association is significant in patients receiving targeted therapy but not in patients receiving chemotherapy or immunotherapy. + read more